Alan McIntyre

Alan McIntyre

Auto-generated profile, based on publicly available information

Alan McIntyre

Hypoxia and Acidosis Group Centre for Cancer Sciences, School of Medicine, BioDiscovery Institute, University of Nottingham, Nottingham, UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Cell Metabolism
Verified
Journal Article
Closed access
EFElena Favaro
Elena Favaro
KBKarim Bensaad
Karim Bensaad
MCMei G. Chong
Mei G. Chong
DTDaniel A. Tennant
Daniel A. Tennant
DFDavid Ferguson
David Ferguson
DFDavid Favara
David Favara

31 May 2012 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
AMAlan McIntyre
Alan McIntyre
SPShalini Patiar
Shalini Patiar
SWSimon Wigfield
Simon Wigfield
JLJi-Liang Li
Ji-Liang Li
ILIoanna Ledaki
Ioanna Ledaki
DFDavid Favara
David Favara
Purpose: Bevacizumab, an anti-VEGFA antibody, inhibits the developing vasculature of tumors, but resistance is common. Antiangiogenic therapy induces hypoxia and we observed increased expression of hypoxia-regulated genes, including carbonic anhydrase IX (CAIX), in response to bevacizumab treatment in xenografts. CAIX expression correlates with poor prognosis in most tumor types and with worse outcome in bevacizumab-treated patients with metastatic colorectal cancer, malignant astrocytoma, and recurrent malignant glioma. Experimental Design: We knocked down CAIX expression by short hairpin RNA in a colon cancer (HT29) and a glioblastoma (U87) cell line which have high hypoxic induction of CAIX and overexpressed CAIX in HCT116 cells which has low CAIX. We investigated the effect on growth rate in three-dimensional (3D) culture and in vivo, and examined the effect of CAIX knockdown in combination with bevacizumab. Results: CAIX expression was associated with increased growth rate in spheroids and in vivo. Surprisingly, CAIX expression was associated with increased necrosis and apoptosis in vivo and in vitro. We found that acidity inhibits CAIX activity over the pH range found in tumors (pK = 6.84), and this may be the mechanism whereby excess acid self-limits the build-up of extracellular acid. Expression of another hypoxia inducible CA isoform, CAXII, was upregulated in 3D but not two-dimensional culture in response to CAIX knockdown. CAIX knockdown enhanced the effect of bevacizumab treatment, reducing tumor growth rate in vivo. Conclusion: This work provides evidence that inhibition of the hypoxic adaptation to antiangiogenic therapy enhances bevacizumab treatment and highlights the value of developing small molecules or antibodies which inhibit CAIX for combination therapy. Clin Cancer Res; 18(11); 3100–11. ©2012 AACR.

1 January 2006 in Cancer Research
Verified
Journal Article
Closed access
PDF file
LLLeendert H. J. Looijenga
Leendert H. J. Looijenga
RHRemko Hersmus
Remko Hersmus
AGAd J.M. Gillis
Ad J.M. Gillis
RPRolph Pfundt
Rolph Pfundt
HSHans J. Stoop
Hans J. Stoop
JOJ. Wolter Oosterhuis
J. Wolter Oosterhuis
Spermatocytic seminomas are solid tumors found solely in the testis of predominantly elderly individuals. We investigated these tumors using a genome-wide analysis for structural and numerical chromosomal changes through conventional karyotyping, spectral karyotyping, and array comparative genomic hybridization using a 32 K genomic tiling-path resolution BAC platform (confirmed by in situ hybridization). Our panel of five spermatocytic seminomas showed a specific pattern of chromosomal imbalances, mainly numerical in nature (range, 3-24 per tumor). Gain of chromosome 9 was the only consistent anomaly, which in one case also involved amplification of the 9p21.3-pter region. Parallel chromosome level expression profiling as well as microarray expression analyses (Affymetrix U133 plus 2.0) was also done. Unsupervised cluster analysis showed that a profile containing transcriptional data on 373 genes (difference of ≥3.0-fold) is suitable for distinguishing these tumors from seminomas/dysgerminomas. The diagnostic markers SSX2-4 and POU5F1 (OCT3/OCT4), previously identified by us, were among the top discriminatory genes, thereby validating the experimental set-up. In addition, novel discriminatory markers suitable for diagnostic purposes were identified, including Deleted in Azospermia (DAZ). Although the seminomas/dysgerminomas were characterized by expression of stem cell–specific genes (e.g., POU5F1, PROM1/CD133, and ZFP42), spermatocytic seminomas expressed multiple cancer testis antigens, including TSP50 and CTCFL (BORIS), as well as genes known to be expressed specifically during prophase meiosis I (TCFL5, CLGN, and LDHc). This is consistent with different cells of origin, the primordial germ cell and primary spermatocyte, respectively. Based on the region of amplification defined on 9p and the associated expression plus confirmatory immunohistochemistry, DMRT1 (a male-specific transcriptional regulator) was identified as a likely candidate gene for involvement in the development of spermatocytic seminomas. (Cancer Res 2006; 66(1): 290-302)

19 February 2015 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
AMAlan McIntyre
Alan McIntyre
DFDavid Favara
David Favara
Anti‐angiogenic therapy has increased the progression‐free survival of many cancer patients but has had little effect on overall survival, even in colon cancer (average 6–8 weeks) due to resistance. The current licensed targeted therapies all inhibit VEGF signalling (Table 1). Many mechanisms of resistance to anti‐VEGF therapy have been identified that enable cancers to bypass the angiogenic blockade. In addition, over the last decade, there has been increasing evidence for the role that the hypoxic and metabolic responses play in tumour adaptation to anti‐angiogenic therapy. The hypoxic tumour response, through the transcription factor hypoxia‐inducible factors (HIFs), induces major gene expression, metabolic and phenotypic changes, including increased invasion and metastasis. Pre‐clinical studies combining anti‐angiogenics with inhibitors of tumour hypoxic and metabolic adaptation have shown great promise, and combination clinical trials have been instigated. Understanding individual patient response and the response timing, given the opposing effects of vascular normalisation versus reduced perfusion seen with anti‐angiogenics, provides a further hurdle in the paradigm of personalised therapeutic intervention. Additional approaches for targeting the hypoxic tumour microenvironment are being investigated in pre‐clinical and clinical studies that have potential for producing synthetic lethality in combination with anti‐angiogenic therapy as a future therapeutic strategy.

1 June 2011 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
Ludwig DuboisLudwig Dubois
Ludwig Dubois
SPSarah Peeters
Sarah Peeters
NLNatasja G. Lieuwes
Natasja G. Lieuwes
NGNele Geusens
Nele Geusens
ATAnne Thiry
Anne Thiry
Philippe LambinPhilippe Lambin
Philippe Lambin

13 June 2016 in Oncogene
Verified
Journal Article
Open access
PDF file
LML L da Motta
L L da Motta
ILI Ledaki
I Ledaki
KPK Purshouse
K Purshouse
SHS Haider
S Haider
MBM A De Bastiani
M A De Bastiani
AMA McIntyre
A McIntyre
The availability of bromodomain and extra-terminal inhibitors (BETi) has enabled translational epigenetic studies in cancer. BET proteins regulate transcription by selectively recognizing acetylated lysine residues on chromatin. BETi compete with this process leading to both downregulation and upregulation of gene expression. Hypoxia enables progression of triple negative breast cancer (TNBC), the most aggressive form of breast cancer, partly by driving metabolic adaptation, angiogenesis and metastasis through upregulation of hypoxia-regulated genes (for example, carbonic anhydrase 9 (CA9) and vascular endothelial growth factor A (VEGF-A). Responses to hypoxia can be mediated epigenetically, thus we investigated whether BETi JQ1 could impair the TNBC response induced by hypoxia and exert anti-tumour effects. JQ1 significantly modulated 44% of hypoxia-induced genes, of which two-thirds were downregulated including CA9 and VEGF-A. JQ1 prevented HIF binding to the hypoxia response element in CA9 promoter, but did not alter HIF expression or activity, suggesting some HIF targets are BET-dependent. JQ1 reduced TNBC growth in vitro and in vivo and inhibited xenograft vascularization. These findings identify that BETi dually targets angiogenesis and the hypoxic response, an effective combination at reducing tumour growth in preclinical studies.